The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...
How to get the Nara and Taro skins in Fortnite How to get the Ryker skin in Fortnite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback